Publications

Access hundreds of peer-reviewed cognitive research papers published by leading neuroscientists using Cogstate technology.

Search

A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia.

Authors: Abi-Dargham A, Carter CS, Cho RY, Girgis RR, Glass A, Kegeles LS, Lieberman JA, Slifstein M, Thompson JL, Van Snellenberg JX, Wall M

Journal: Journal of Psychopharmacology

Year Published: 2016

BACKGROUND: Evidence from preclinical and human studies indicates the presence of reduced dopamine-1 receptor (D1R) signaling in the cortex, where D1Rs predominate, in patients with schizophrenia (SCZ), which may contribute to their cognitive deficits. Furthermore, studies in nonhuman primates (NHP) have suggested that intermittent administration of low doses of D1R agonists produce long-lasting reversals in […]

2014 Report on the Milestones for the US National Plan to Address Alzheimer’s Disease.

Authors: Aisen P, Albert M, Au R, Bain LJ, Carrillo MC, Corrada MM, DeKosky S, Drachman D, Fargo KN, Fillit H, Gitlin L, Haas M, Herrup K, Kawas C, Khachaturian AS, Khachaturian ZS, Klunk W, Knopman D, Kukull WA, Lamb B, Logsdon RG, Maruff P, Mesulam M, Mobley W, Mohs R, Morgan D, Nixon RA, Paul S, Petersen R, Plassman B, Potter W, Reiman E, Reisberg B, Sano M, Schindler R, Schneider LS, Snyder PJ, Sperling RA, Thies WH, Yaffe K

Journal: Alzheimer's & Dementia

DOI: 10.1016/j.jalz.2014.08.103

Year Published: 2014

With increasing numbers of people with Alzheimer’s and other dementias across the globe, many countries have developed national plans to deal with the resulting challenges. In the United States, the National Alzheimer’s Project Act, signed into law in 2011, required the creation of such a plan with annual updates thereafter. Pursuant to this, the US […]

A combination of physical activity and computerized brain training improves verbal memory and increases cerebral glucose metabolism in the elderly.

Authors: Campbell A, Cheetham C, Darby D, Dhaliwal S, Martins RN, Maruff P, Putland E, Shah T, Sohrabi H, Verdile G, Weinborn M

Journal: Translational Psychiatry

DOI: 10.1038/tp.2014.122

Year Published: 2014

Physical exercise interventions and cognitive training programs have individually been reported to improve cognition in the healthy elderly population; however, the clinical significance of using a combined approach is currently lacking. This study evaluated whether physical activity (PA), computerized cognitive training and/or a combination of both could improve cognition. In this nonrandomized study, 224 healthy […]

A comparative study of two acoustic measures of hypernasality.

Authors: Ibrahim HM, Kilpatrick N, Reilly S, Vogel AP

Journals: Journal of Speech, Language

DOI: 10.1044/1092-4388(2009/08-0161)

Year Published: 2009

PURPOSE: This study aimed to compare 2 quantitative acoustic measures of nasality in children with cleft lip and palate (CLP) and healthy controls using formalized perceptual assessment as a guide. METHOD: Fifty participants (23 children with CLP and 27 age- and gender-matched healthy controls) aged between 4 and 12 years produced a variety of high […]

A Comparison of Four Computerized Neurocognitive Assessment Tools to a Traditional Neuropsychological Test Battery in Service Members with and without Mild Traumatic Brain Injury.

Authors: Arrieux JP, Cole WR, Ivins BJ, Qashu FM, Schwab KA

Journal: Archives of Clinical Neuropsychology

DOI: 10.1093/arclin/acx036

Year Published: 2017

Objective: Computerized neurocognitive assessment tools (NCATS) are often used as a screening tool to identify cognitive deficits after mild traumatic brain injury (mTBI). However, differing methodology across studies renders it difficult to identify a consensus regarding the validity of NCATs. Thus, studies where multiple NCATs are administered in the same sample using the same methodology […]

A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia.

Authors: Maruff P, Norman T, Olver J, Pietrzak RH, Piskulić D, Snyder PJ

Journal: Journal of Clinical and Experimental Neuropsychology

DOI: 10.1080/13803390802592458

Year Published: 2009

This study examined the criterion and construct validity of a brief computerized cognitive test battery (CogState Schizophrenia Battery) compared to a conventional cognitive test battery recommended by the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) consensus. The CogState and MATRICS batteries yielded comparable effect sizes in comparing patients with schizophrenia to healthy […]

A Cross-Sectional Analysis of Students’ Intuitions When Interpreting CIs.

Authors: Cumming G, Kalinowski P, Lai J

Journal: Frontiers in Psychology

DOI: 10.3389/fpsyg.2018.00112

Year Published: 2018

We explored how students interpret the relative likelihood of capturing a population parameter at various points of a CI in two studies. First, an online survey of 101 students found that students’ beliefs about the probability curve within a CI take a variety of shapes, and that in fixed choice tasks, 39% CI [30, 48] […]

A cross-sectional study to evaluate the association of hyperbilirubinaemia on markers of cardiovascular disease, neurocognitive function, bone mineral density and renal markers in HIV-1 infected subjects on protease inhibitors.

Authors: Asboe D, Barber TJ, Boffito M, Hill A, Jagjit Singh G, Moyle G, Nelson M, Scourfield A, Waters L, Yapa HM

Journal: HIV Clinical Trials

DOI: 10.1080/15284336.2016.1176305

Year Published: 2016

BACKGROUND: Ongoing inflammation in controlled HIV infection contributes to non-AIDS comorbidities. High bilirubin appears to exhibit an anti-inflammatory effect in vivo. We therefore examined whether increased bilirubin in persons with HIV was associated with differences in markers of inflammation and cardiovascular, bone, renal disease, and neurocognitive (NC) impairment. METHODS: This cross-sectional study examined inflammatory markers […]

A Newly Designed Mobile-Based Computerized Cognitive Addiction Therapy App for the Improvement of Cognition Impairments and Risk Decision Making in Methamphetamine Use Disorder: Randomized Controlled Trial.

Authors: Chen T, Du J, Jiang H, Li R, Li X, Su H, Tan H, Xu D, Yan H, Zhao M., Zhong N, Zhu Y

Journal: JMIR mHealth and uHealth

DOI: 10.2196/10292

Year Published: 2018

BACKGROUND: Cognitive rehabilitation therapy has been found to improve cognitive deficits and impulse control problems in methamphetamine use disorder (MUD). However, there is limited research regarding this therapy’s feasibility when using mobile-based health technologies in supporting recovery from MUD in China. OBJECTIVE: The main aim of this study was to test whether 4 weeks of […]

A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder.

Authors: Drouillard A, Fava M, Flynn M, Hand H, Hoeppner B, Johe K, Kashambwa R, Kay G, Martinson MA, Papakostas GI, Russo P, Yeung A

Journal: Molecular Psychiatry

DOI: 10.1038/s41380-018-0334-8

Year Published: 2019

NSI-189 is a novel neurogenic compound independent of monoamine reuptake pathways. This trial evaluated oral NSI-189 as monotherapy in major depressive disorder. To improve signal detection, the sequential-parallel comparison design (SPCD) was chosen. Two hundred and twenty subjects were randomized to NSI-189 40 mg daily, 80 mg daily, or placebo for 12 weeks. The primary outcome measure […]

Tags

There are no tags for this publication.

A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy.

Authors: Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Grove RA, Horrigan JP, Jarskog LF, Kantrowitz JT, Keefe RS, Keshavan MS, Laurelle M, Lieberman JA, Lowy MT, Marder SR, Maruff P, McMahon RP, Peykamian MA, Seidman LJ

Journal: Schizophrenia Research

DOI: 10.1016/j.schres.2015.01.041.

Year Published: 2015

This Phase II exploratory study assessed GSK239512, a brain penetrant histamine H3 receptor antagonist, versus placebo on cognitive impairment in 50 stable outpatients with schizophrenia. Subjects were randomized to placebo or GSK239512 for 7weeks (4weeks titration). GSK239512 was associated with a small positive effect size (ES) on the CogState Schizophrenia Battery (CSSB) Composite Score (ES=0.29, […]

A pilot evaluation of a computer-based psychometric test battery designed to detect impairment in patients with cirrhosis.

Authors: Cook NA, Crossey MM, Harel BT, Kim JU, Kimhofer T, Pasha Y, Schembri AJ, Taylor-Robinson SD

Journal: International Journal of General Medicine

DOI: 10.2147/IJGM.S140197

Year Published: 2017

BACKGROUND: Psychometric testing is used to identify patients with cirrhosis who have developed hepatic encephalopathy (HE). Most batteries consist of a series of paper-and-pencil tests, which are cumbersome for most clinicians. A modern, easy-to-use, computer-based battery would be a helpful clinical tool, given that in its minimal form, HE has an impact on both patients’ […]

A pilot study of the neuropsychological benefits of computerized cognitive rehabilitation in Ugandan children with HIV.

Authors: Bangirana P, Boivin MJ, Busman RA, Giordani B, Opoka RO, Page CF, Parikh SM

Journal: Neuropsychology

DOI: 10.1037/a0019312

Year Published: 2010

OBJECTIVE: Because antiretroviral treatment (ART) fails to improve neurocognitive impairment in children with HIV, we completed a pilot study evaluating the feasibility and cognitive benefit of computerized cognitive rehabilitation therapy (CCRT) in Ugandan children with HIV. METHOD: Sixty Ugandan children with HIV (23 on ART) were randomly assigned to 10 sessions of Captain’s Log CCRT […]

A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.

Authors: Azulay JP, Berg D, Broussolle E, Ceballos-Baumann A, Corvol JC, Defebvre L, Derkinderen P, Di Paolo T, Durif F, Eggert K, Espay AJ, Feigin A, Feuerbach D, Geny C, Gomez-Mancilla B, Gostkowski M, Hockey HU, Houeto JL, Jaeger J, Jakab A, Johns D, Linazasoro G, Maruff P, Rascol O, Rozenberg I, Schwarz J, Sovago J, Stocchi F, Storch A, Tranchant C, Trenkwalder C, Weiss M, Zhang L

Journal: Movement Disorders

DOI: 10.1002/mds.26569.

Year Published: 2016

BACKGROUND: This phase 2 randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of the nicotinic acetylcholine receptor α7 agonist AQW051 in patients with Parkinson’s disease and levodopa-induced dyskinesia. METHODS: Patients with idiopathic Parkinson’s disease and moderate to severe levodopa-induced dyskinesia were randomized to AQW051 10 mg (n = 24), AQW051 50 mg (n = […]

A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer’s Disease.

Authors: Ames D, Burnham SC, Groth D, Laws SM, Lim YY, Martins RN, Maruff P, Masters CL, Milicic L, Peretti M, Porter T, Rainey-Smith S, Rowe CC, Salvado O, Savage G, Taddei K, Verdile G, Villemagne VL

Journal: Frontiers in Aging Neuroscience

DOI: 10.3389/fnagi.2018.00423

Year Published: 2018

Studies of Alzheimer’s disease risk-weighted polygenic risk scores (PRSs) for cognitive performance have reported inconsistent associations. This inconsistency is particularly evident when PRSs are assessed independent of APOE genotype. As such, the development and assessment of phenotype-specific weightings to derive PRSs for cognitive decline in preclinical AD is warranted. To this end a episodic memory-weighted […]

A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia.

Authors: Abi-Dargham A, Carter CS, Cho RY, Girgis RR, Glass A, Kegeles LS, Lieberman JA, Slifstein M, Thompson JL, Van Snellenberg JX, Wall M

Journal: Journal of Psychopharmacology

Year Published: 2016

BACKGROUND: Evidence from preclinical and human studies indicates the presence of reduced dopamine-1 receptor (D1R) signaling in the cortex, where D1Rs predominate, in patients with schizophrenia (SCZ), which may contribute to their cognitive deficits. Furthermore, studies in nonhuman primates (NHP) have suggested that intermittent administration of low doses of D1R agonists produce long-lasting reversals in […]